Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Spero Therapeutics, Inc. - Common Stock (NQ:SPRO)

0.6940 -0.0260 (-3.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Spero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Earnings Scheduled For March 27, 2025
Via Benzinga
A Glimpse of Spero Therapeutics's Earnings Potential
Via Benzinga
The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts
Via Benzinga
What 4 Analyst Ratings Have To Say About Spero Therapeutics
Via Benzinga
Spero Therapeutics's Earnings Outlook
Via Benzinga
Recap: Spero Therapeutics Q4 Earnings
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024
SPRO stock results show that Spero Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
3 Micro-Cap Moonshots for Fearless Investors
Investors should know the risks of micro-cap stocks before looking into these three high-potential companies with low prices. 
Via InvestorPlace
Earnings Outlook For Spero Therapeutics
Via Benzinga
Recap: Spero Therapeutics Q3 Earnings
Via Benzinga
Earnings Outlook For Spero Therapeutics
Via Benzinga
4 Analysts Have This to Say About Spero Therapeutics
Via Benzinga
SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024
SPRO stock results show that Spero Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
Via Benzinga
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Robinhood Markets, Inc. (NASDAQ: HOOD) rose sharply in today’s pre-market trading after the company reported February trading metrics. 
Via Benzinga
Spero Therapeutics's Earnings: A Preview
Via Benzinga
Recap: Spero Therapeutics Q1 Earnings
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of all the biggest pre-market stock movers worth watching on Thursday morning! 
Via InvestorPlace
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Spero Therapeutics: Here's What You Need To Know
Via Benzinga
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.